Compounded GLP-1s in 2026: What the 503B Decision Means

The Short Version: Status as of Mid-2026

Here is the regulatory picture in plain terms:

This is a developing regulatory matter. Nothing here is medical guidance, and the dates and findings reflect the public record as of late June 2026.

What "503A" and "503B" Actually Mean

The terms 503A and 503B come from sections of the Federal Food, Drug, and Cosmetic Act. They describe two different kinds of compounding, and the distinction is central to this story.

503A pharmacies are traditional compounding pharmacies. They make a customized preparation for an individual patient based on a specific prescription. Think of a pharmacist adjusting a dose or removing an allergen for one named person. These preparations are not FDA-approved products, and 503A compounding is generally limited to patient-specific needs.

503B outsourcing facilities are a different category created by Congress in 2013. They can compound larger batches without a patient-specific prescription and sell to clinics and providers, but they must register with the FDA, follow current good manufacturing practice (CGMP) standards, and they may only compound from bulk substances that appear on the FDA's 503B Bulks List (or that meet other narrow criteria).

The May 1, 2026 proposal concerns that 503B Bulks List specifically. By declining to add semaglutide, tirzepatide, and liraglutide to it, the FDA would remove the pathway that allowed outsourcing facilities to mass-produce these GLP-1s. The table below summarizes the contrast.

|---|---|---|

A crucial point for compliance and clarity: compounded versions of these drugs, whether made under 503A or 503B, are not FDA-approved products. They have not gone through the agency's approval process for safety, efficacy, and manufacturing quality the way the brand-name versions have. Treating a compounded copy as equivalent to an approved drug is exactly the assumption the FDA has objected to.

Why the Shortages Mattered So Much

The entire era of widely available compounded GLP-1s traces back to supply. When demand for semaglutide and tirzepatide outstripped the manufacturers' production capacity, the FDA listed them as in shortage. Under the law, being on the shortage list opens a temporary door: pharmacies and outsourcing facilities can compound copies of a drug that is otherwise commercially unavailable, on the rationale that patients need access.

That door began to close as supply caught up:

Once a medication is off the shortage list, the central legal justification for compounding it disappears. The May 2026 proposal is the next logical step in that sequence: with supply stabilized and shortages resolved, the FDA concluded there is no clinical need to keep these substances available for bulk compounding through the 503B pathway. Brand-name supply stabilizing is precisely why the agency reached a "no clinical need" finding.

What This Means If You Are Currently on a Compounded GLP-1

If you are currently using a compounded GLP-1, the most important and the only appropriate next step is to talk with the prescriber or provider who manages your care. This is a clinician-directed decision, and the right path depends on your individual medical situation, which only your provider can assess.

In general terms, what the regulatory change points toward is a transition. As shortages resolved and brand-name supply stabilized, the clinician-directed options that exist within the FDA-approved system became more available than they were during the shortage period. Some people work with their providers on a transition to brand-name products; others discuss alternative clinician-directed options. None of that is something this article can or should prescribe.

What this article will not do is tell you how to keep obtaining compounded product or how to stockpile anything. That is outside the scope of an education and tracking resource, and it would run against the spirit of the regulatory change. The constructive move is to bring good data to your provider conversation, which is where tracking comes in.

What to Track: Biomarkers Worth Monitoring

Whether you are on a brand-name GLP-1, transitioning, or simply following this space, the value of a clean longitudinal record does not change. People using GLP-1 medications, working alongside their providers, commonly keep an eye on metabolic and safety-relevant markers over time. The following are biomarkers researchers and clinicians frequently discuss in the context of GLP-1 therapy. None of this is a recommendation to test or treat; it is a list of what is commonly tracked so you can organize your own data and discuss it with your provider.

Tracking these consistently, rather than as scattered one-off results, is what makes the data genuinely useful in a clinical conversation. A single value is a snapshot; a trend line tells a story. If you want a structured starting point, our [semaglutide blood work guide](/blog/semaglutide-blood-work-guide) and [tirzepatide blood work guide](/blog/tirzepatide-blood-work-guide) walk through the markers commonly discussed for each, and you can browse the full [biomarker library](/biomarkers) for plain-language explanations of each test.

[Track your protocol and labs in one place with MyProtocolStack.](/auth/login?mode=signup)

How This Fits the Broader 2026 Regulatory Picture

The GLP-1 compounding decision does not stand alone. 2026 has been an active year for peptide and compounding regulation more broadly, and several substances have seen their compounding status reconsidered as the FDA works through its bulk-substance evaluations. If you want the wider context, we maintain an overview of the [reclassified peptides of 2026](/blog/all-14-reclassified-peptides-2026) that situates the GLP-1 decision among the other changes.

The throughline across all of it is consistent: as shortages resolve and the FDA completes its formal evaluations, the temporary latitude that allowed broad compounding narrows back toward the standard framework, in which FDA-approved products are the default and compounding fills specific, documented gaps. For people tracking their health seriously, the practical takeaway is to keep your records clean and provider-ready regardless of which way any individual decision lands. You can explore structured overviews of individual compounds in the [peptide library](/peptides).

Frequently Asked Questions

Is compounded semaglutide or tirzepatide still legal in 2026?

As of mid-2026, the situation is in transition. On May 1, 2026, the FDA published a proposed action declining to add semaglutide, tirzepatide, and liraglutide to the 503B Bulks List, which would end large-scale outsourcing-facility compounding of these drugs. The proposal is not yet finalized, and the public comment period was extended to July 30, 2026. Because this is a fast-moving regulatory matter, you should rely on your prescriber and the official FDA record for the current status.

Why is the FDA moving to stop compounding of these GLP-1s?

The legal basis for widely compounding semaglutide and tirzepatide rested on their being on the FDA drug shortage list. The semaglutide shortage ended in February 2025 and tirzepatide's resolved earlier. With supply stabilized, the FDA found "no clinical need" to keep these substances available for bulk 503B compounding, since the brand-name approved products are now commercially available.

What is the difference between 503A and 503B compounding?

503A refers to traditional pharmacy compounding of a patient-specific preparation made for one individual based on a prescription. 503B refers to registered outsourcing facilities that can compound larger batches without a patient-specific prescription, follow CGMP manufacturing standards, and may only use bulk substances permitted by the FDA. The May 2026 proposal concerns the 503B Bulks List directly. Neither pathway produces an FDA-approved product.

Does this mean compounded GLP-1s were FDA-approved before?

No. Compounded versions of semaglutide and tirzepatide have never been FDA-approved. They were permitted under the temporary latitude tied to the drug shortage list, not because they passed FDA review for safety, efficacy, and manufacturing quality. Treating a compounded copy as equivalent to the approved brand-name product is the assumption the FDA has specifically objected to.

I am currently using a compounded GLP-1. What should I do?

Talk with the prescriber or provider who manages your care. This is a clinician-directed decision that depends on your individual medical situation. MyProtocolStack does not provide medical advice and cannot tell you what to take or where to obtain it. What you can do on your own is keep an organized record of your protocol and relevant lab markers over time, so your provider conversation is grounded in good data.

Sources

1. Federal Register, "List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act," May 1, 2026. https://www.federalregister.gov/documents/2026/05/01/2026-08552/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal

2. Federal Register, comment-period extension notice, June 26, 2026. https://www.federalregister.gov/documents/2026/06/26/2026-12937/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal

3. U.S. Food and Drug Administration, press announcement: "FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide from 503B Bulks List." https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list

4. Pharmacy Times, "FDA Moves to Permanently Close the Door on Compounded GLP-1s." https://www.pharmacytimes.com/view/fda-moves-to-permanently-close-the-door-on-compounded-glp-1s

5. Epstein Becker Green, Health Law Advisor, "FDA Proposal Would Leave Semaglutide, Tirzepatide, and Liraglutide Off 503B Bulks List." https://www.healthlawadvisor.com/fda-proposal-would-leave-semaglutide-tirzepatide-and-liraglutide-off-503b-bulks-list

*MyProtocolStack is a tracking and education tool, not medical advice, diagnosis, or treatment, and you should always consult a qualified healthcare professional before making any changes to your health protocol.*